Neurology
Supporting studies across neurological disorders and central nervous system indications.
Experience across 30+
therapeutic areas
From common indications to rare and highly specialised ones, our teams have worked across the full range: oncology, orphan and paediatric programmes, biosimilars and medical devices. Whatever your indication, we have handled the design and analysis challenges it brings.
Deep therapeutic expertise across the development lifecycle
Our biometrics and data expertise spans a wide range of therapeutic areas, supporting complex programmes from early phase to post-approval.
Ophthalmology
Experience supporting ophthalmic therapies and vision-related clinical development.
Endocrinology
Supporting endocrine and hormonal-disease programmes.
Cardiovascular & Metabolic
Cardiovascular, metabolic and related risk-factor studies across development phases.
Gastroenterology
Gastrointestinal and hepatobiliary research across acute and chronic indications.
Nephrology
Experience across renal disorders and kidney-related clinical development.
Urology
Supporting urological studies across diverse patient populations.
Gynaecology
Supporting women's reproductive health and gynaecological research.
Dermatology
Dermatological therapies across inflammatory and chronic skin conditions.
Cell & Gene Therapy
Supporting advanced therapies from early development through clinical delivery.
Oncology & Haematology
Extensive experience across solid tumours, haematology and complex oncology programmes.
Infectious Diseases
Supporting infectious disease programmes across diverse therapeutic settings.
Immunology
Supporting immune-mediated diseases and advanced immunological therapies.
Rare Diseases
Specialised programmes across rare diseases and emerging therapeutic indications.
We bring therapeutic context into the design
Our indication experience helps shape the choices that matter, from endpoints and analysis strategy to how the evidence is interpreted and presented.
Indication-specific SAPs
Our senior biostatisticians develop SAPs around the realities of the indication, not from a generic template, so the analysis reflects the endpoints, data and questions that matter for the study.
Design choices that hold up
Endpoints, estimands and adaptive approaches are considered in the context of the therapeutic area, with regulatory expectations in view from the start.
The right team for the indication
We build each team around relevant therapeutic experience, bringing together biostatistics, programming, data management and medical writing expertise that fits the programme.
Regulatory experience built in
For orphan, paediatric, medical device and biosimilar programmes, we bring experience of the specific regulatory pathways and evidence requirements that shape development.
Specialist studies, shaped by
the right methodology
Beyond the major therapeutic areas, we support specialist study types and drug modalities that call for a more tailored approach.
Small Molecules
Supporting small molecule development.
Biosimilars
Biometrics for biosimilar and generic programmes.
Medical Devices
Clinical evidence for innovative medical devices.
Paediatric Trials
Experience across paediatric clinical development.